2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- manufacturers
- YLT192
-
- $2500.00
-
2026-07-27
- CAS:1246566-47-1
- Purity:
- Supply Ability: 10g
|
| | 2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- Basic information |
| | 2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- Chemical Properties |
| Boiling point | 529.8±50.0 °C(Predicted) | | density | 1.272±0.06 g/cm3(Predicted) | | pka | 12.70±0.70(Predicted) |
| | 2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- Usage And Synthesis |
| Description | YLT192 is an orally active and bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy. | | Uses | YLT192 is an orally active and highly bioavailable VEGFR2 inhibitor with potent anti-angiogenic activity and anti-tumor efficacy. YLT192 significantly inhibited the kinase activity of VEGFR2 and inhibited the proliferation, migration, invasion and tube formation of human umbilical cord vascular endothelial cells. YLT192 also inhibited VEGF-induced VEGFR2 phosphorylation and its downstream signaling regulators. YLT192 also showed the ability to inhibit angiogenesis in vivo in zebrafish embryo models and alginate-coated tumor cell experiments. YLT192 can directly inhibit the proliferation of cancer cells and induce their apoptosis[1]. | | References | [1] YLT192, a novel, orally active bioavailable inhibitor of VEGFR2 signaling with potent antiangiogenic activity and antitumor efficacy in preclinical models |
| | 2-Pyridinecarboxamide, 4-[4-[(3-methoxybenzoyl)amino]phenoxy]-N-methyl- Preparation Products And Raw materials |
|